MAPT and supranuclear palsy, progressive, 1: However, the co-localization of [18F]ACI-12589 signals in AD in vivo and in PSP with [18F]RO948 (a tau–PET ligand) may reflect off-target binding to neurodegenerative processes downstream of tau [103].